Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology.
The acquisition of Ablynx (June 2018) continues Sanofis commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynxs Nanobody development programmes